 The FDA has approved Beyond Air Incs NASDAQ: XAIR LungFit PH to treat term and near-term neonates with hypoxic respiratory failure often referred to as persistent pulmonary hypertension of the newborn or PPHN. LungFit PH is the initial device from the LungFit. 